Relapsed and Refractory Follicular Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed and Refractory Follicular Lymphoma
| Record | Firm | Date |
|---|---|---|
| Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) (NCT04989621) | Sun Yat-sen University | 2021-08-01 |
Track Relapsed and Refractory Follicular Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.